STEMCELL Technologies receives grant for cell isolation technology
The company said the development of cell isolation technology would help further research on HIV, as well as other infectious diseases. The technology would give access to immune cells from HIV-infected patients and enable researchers to study immune responses and ultimately develop vaccines.
"These products will have a real impact on the treatment of HIV," Dr. Steven Woodside, the director of particle chemistry and engineering R&D at STEMCELL, said. "Because they will be versatile, robust and inexpensive they will be more practical for use in point-of-care diagnostics to support field work in resource-limited regions of the world and for high-throughput screening of patient samples."
STEMCELL Technologies President and CEO Dr. Allen Eaves said the project will contribute to an HIV-free future and have immediate impact on the Canadian economy by enabling the company to create jobs and technology
"We are grateful to the government of Canada for its investment in this project, which supports our commitment to the development of products that enable breakthroughs in HIV research" Eaves said.